3D Bioprinting for Medical Applications
A special issue of Journal of Functional Biomaterials (ISSN 2079-4983). This special issue belongs to the section "Biomaterials for Tissue Engineering and Regenerative Medicine".
Deadline for manuscript submissions: 30 September 2024 | Viewed by 83
Special Issue Editors
Interests: bioprinting; pancreatic islets; tissue models; pancreas; biomaterials; stem cells; medical application
Special Issue Information
Dear Colleagues,
Bioprinting is a rapidly developing field of tissue engineering and modern regenerative medicine. Three-dimensional bioprinting using living cells and appropriate biomaterials is one of the increasingly used technologies for the regeneration of hard tissues and the production of bionic organs and tissue models. In parallel with the development of new bioprinting techniques, there is an intensive development of biomaterials and full bioink compositions that provide an appropriate environment for cells. The intensive development of new technologies and biomaterials allows us to think about bioprinting entire organs and using them in clinical practice. Bioprinted organs and smaller models may also contribute to revolutionizing preclinical testing of new drugs and active substances. The possibility of testing new drugs on bioprinted models will not only reduce the number of animals used for research, but above all, it will help us to discover new opportunities for pharmaceutical sciences and basic research. However, despite numerous studies and reports, there is still much to discover, and this requires scientists to take an interdisciplinary approach to their research. Despite advanced work and promising results of preclinical studies, the clinical use of bioprinted constructs and whole organs is still in the research phase. In particular, stem cells are being increasingly used in bioprinting research.
In this Special Issue, we would like to present a collection of articles detailing the latest developments and trends in 3D bioprinting research for medical applications, paying particular attention to the development of innovative bioinks, new cross-linking mechanisms, and cell viability and differentiation intended to create bionic constructs. In this Special Issue, we want to focus on the possibility of using these achievements in transplantation medicine, for basic and preclinical research of new drugs and the toxicity of active substances.
Dr. Marta Klak
Dr. Michal Wszoła
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Functional Biomaterials is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- tissue models
- bionic organs
- bioprinted constructs
- regenerative medicine
- drug testing
- tissue-engineered products (TEP)
- stem cells
